FDA Advisory Committee Statements: 3 Companies Compared
By Kyle Porter, Executive Vice President & Managing Director.
Updated November 20, 2026

Three 2026 FDA advisory committee statements compared: Replimune, Moderna and Capricor. What each headline said, how the vote was described, who was quoted and what happened next.
How do companies word a statement after an FDA advisory committee vote? In 2026, Replimune and Moderna put the favorable vote in the release headline, while Capricor, after a 9 to 3 vote against, titled its release an update. All three quoted the chief executive and pointed to the FDA's final decision. The statements differed most in how they described what the vote question covered.
Last updated: November 20, 2026. Vote counts and quotes come from the companies' own releases and trade press named in the text. Regulatory status can change after publication. This is communications guidance, not legal or securities advice.
Key takeaways
-
Replimune (10 to 3 in favor) and Moderna (9 to 0 twice) led their headlines with the vote. Capricor (3 to 9 against) did not.
-
Capricor's release said the vote question covered a narrower indication than the company had proposed, and it highlighted separate committee feedback on upper limb function.
-
A committee vote is non-binding. Moderna's release said so directly, and each company restated the FDA action date.
-
The outcomes differed again after the votes: Replimune and Moderna were approved in August 2026, and Capricor's action date was extended to November 22, 2026.
Contents
What did each company say after its vote?
Each company issued a release within a day of its committee meeting, quoted its chief executive and named the next FDA date. The table sets out the facts from the three releases.
CompanyCommittee and dateVoteRelease headlineExecutive quoted
Replimune (RP1 with nivolumab, advanced melanoma)Cellular, Tissue, and Gene Therapies Advisory Committee, July 30, 202610 to 3 in favor"Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma"Sushil Patel, Ph.D., chief executive officer Moderna (mRNA-1010, seasonal influenza vaccine)Vaccines and Related Biological Products Advisory Committee, June 18, 20269 to 0 for adults 50 to 64, and 9 to 0 for adults 65 and older"Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine"Stéphane Bancel, chief executive officer Capricor (deramiocel, Duchenne muscular dystrophy)Cellular, Tissue and Gene Therapies Advisory Committee, July 29, 2026 (release dated July 30)3 for, 9 against, 0 abstain"Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel"Linda Marbán, Ph.D., chief executive officer
The Replimune and Moderna releases are dated July 30 and June 18, 2026. The Capricor meeting date comes from AJMC's July 30, 2026 report, and the vote count comes from Capricor's release. The committee names are as the companies gave them.
How did the headlines handle the vote?
The headlines split into two approaches: two put the outcome in the title, and one used a neutral word. Replimune wrote "favorable outcome" and Moderna wrote "votes unanimously in favor of the benefit-risk profile." Capricor wrote "provides update."
The choice matters because headlines are what wire services, search results and alerts show first. A reader who sees only "Provides Update" learns nothing about the result and must open the release. Capricor's body then reports the 3 to 9 vote in its second part, with the company's reading of the evidence beside it.
The practical lesson is that a neutral headline after a negative vote is accurate but invites a search for the number. Investors and reporters will find the vote count in the FDA's own materials and trade press, so the release is better when the count is easy to find and the company's view follows it. The guide to FDA communications PR covers matching wording to the FDA record.
How did each company describe the vote question?
Each company described the question in its own words, and the description shaped how the vote read. The three approaches were quite different.
-
Replimune said the question was whether the efficacy results from the IGNYTE study are evaluable and clinically meaningful, and added that the committee had also discussed whether the single-arm design allows a reliable estimate of response rate and durability. The release gave no response rate figures.
-
Moderna described the question as whether the vaccine's benefits outweigh its risks, asked separately for adults 50 to 64 and for adults 65 and older. The release paraphrased the question and did not give the exact wording.
-
Capricor described the question as whether the available evidence supported effectiveness for cardiomyopathy in patients with Duchenne muscular dystrophy. The release said that question addressed a narrower indication than the company had proposed and did not include a vote on overall benefit-risk.
Capricor also reported a second discussion. The committee's feedback on upper limb function was described in the release as "directionally supportive" of the Phase 3 HOPE-3 trial evidence, including the PUL 2.0 primary endpoint. AJMC's July 30, 2026 report framed the day's result as a vote against approval for the cardiomyopathy indication. Both descriptions are on the record, and a reader needs both to see the full picture.
The common thread is precision. A statement that names the exact question, says what it did not cover, and separates that from other discussion is harder to attack later than one that blends them. The topline release guide, biotech topline data releases compared, shows the same principle applied to trial results.
What happened after each vote?
The FDA decided differently in each case, and the votes did not predict the order of events. Advisory committee recommendations are non-binding, as Moderna's release stated.
CompanyFDA action date named in the releaseWhat followedSource
ReplimuneAugust 2, 2026 (Class 1 resubmission)Accelerated approval on August 6, 2026 for TUDRIQEV (vusolimogene oderparepvec-wtpg), previously RP1, in combination with nivolumabReplimune's 10-Q for the quarter ended September 30, 2026 ModernaAugust 5, 2026Approval of mFLUSIVA for adults 50 and older, with accelerated approval for adults 65 and older based on immune responses and a postmarketing confirmatory trialModerna's August 5, 2026 release CapricorAugust 22, 2026FDA extended the action date to November 22, 2026 after a major amendment with additional HOPE-3 data supporting a narrower indication focused on upper limb functionRare Daily, August 24, 2026
Two lessons follow. First, Replimune's action date moved from August 2 to an approval on August 6, so a date named in a release is a target, not a promise. Second, Capricor's company position and the FDA's later treatment of new data show why a statement should stay accurate over months, not days. As of November 20, 2026, no later decision for Capricor appeared in the sources reviewed, and the date may change.
What should an advisory committee statement include?
An advisory committee statement should include the vote count, the question voted on, a chief executive quote, the non-binding status and the next FDA date. The checklist below draws on the three releases and is a drafting aid, not a template that fits every case.
-
Draft two versions before the meeting, one for a favorable vote and one for an unfavorable vote, and have counsel review both.
-
State the vote count in the first two paragraphs, using the committee's own numbers.
-
Name the question voted on. If the question was narrower or broader than your application, say so plainly, as Capricor did.
-
Say that the recommendation is non-binding and name the FDA action date, as Moderna did.
-
Quote one executive in one or two sentences. Avoid claims the FDA record does not support.
-
Keep other committee feedback separate from the vote, and label it as discussion, not a vote.
-
Update the company website, investor page and media contacts with the same facts the day the release goes out.
-
Plan the next release now. A date extension, a complete response letter or an approval each needs its own statement, as covered in the clinical-stage biotech PR rules.
Investor communications rules also apply to what executives say on the day. The guide to investor relations and the related piece on biotech financing announcements cover how to keep a company's statements consistent when news affects its stock and its financing.
Frequently asked questions
Is an FDA advisory committee vote binding?
No. Moderna's June 18, 2026 release stated that advisory committee recommendations are non-binding and that the FDA makes the final approval decision.
Should the headline include the vote result?
Often yes. Replimune and Moderna put the outcome in their headlines, while Capricor used a neutral word after a 9 to 3 vote against. Readers see the headline first, so state the result clearly.
What did the three committees vote on?
Replimune's committee voted on whether IGNYTE efficacy results are evaluable and clinically meaningful. Moderna's voted on benefit versus risk for two age groups. Capricor's voted on effectiveness for Duchenne cardiomyopathy.
Did a favorable vote lead to approval?
In two of the three cases. Moderna's mFLUSIVA was approved on August 5, 2026, and Replimune's TUDRIQEV received accelerated approval on August 6, 2026, four days after the date named in its release.
What happened to Capricor after the negative vote?
The FDA extended the action date to November 22, 2026 after Capricor submitted additional HOPE-3 data supporting a narrower indication, according to Rare Daily on August 24, 2026.
Who should approve an advisory committee statement?
The chief executive, the head of investor relations and legal counsel should approve every line before release. The statement is also an investor communication, so counsel should review both the favorable and unfavorable drafts in advance.
Before your next meeting, write both versions of the release and have counsel clear them. The company that drafts the unfavorable statement in advance is the one that can issue an accurate headline within hours.
Follow us
LinkedIn





